Q2 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- BioCryst Pharmaceuticals Inc (BCRX) reported its best quarter for ORLADEYO since its approval, with significant revenue growth and increased patient demand.
- The company achieved a 45% year-over-year growth in ORLADEYO revenue, driven by new patient prescriptions, improved efficiency in paid shipments, and strong international results.
- BioCryst Pharmaceuticals Inc (BCRX) is on track to reach the upper half of its revenue guidance of $580 million to $600 million for the full year, even after the sale of its European business.
- The company has a strong financial position, having paid down significant portions of its term debt, and expects to generate $700 million in cash by 2027.
- BioCryst Pharmaceuticals Inc (BCRX) is leveraging its commercial capabilities to become a consolidator of rare disease assets, with plans to deploy capital into value-creating opportunities.
- The company faces potential challenges with the discontinuation rate, although it has remained stable, there is always a risk of patients moving to other therapies.
- There is uncertainty regarding the impact of new HAE treatments like garadacimab and Ekterly on ORLADEYO's demand.
- The pediatric PDUFA date for ORLADEYO granules has been delayed to December 12, which could impact future revenue projections.
- BioCryst Pharmaceuticals Inc (BCRX) will not have European revenue in the fourth quarter due to the sale of its European business, which could affect overall revenue figures.
- The company is entering a competitive market for rare disease assets, which could pose challenges in acquiring new products or companies at favorable terms.
Good day, and welcome to the BioCryst second-quarter 2025 earnings conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to John Bluth. Please go ahead.
Thank you very much. Good morning, and welcome to BioCryst's second-quarter 2025 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; President and Chief Commercial Officer, Charlie Gayer; Chief R&D Officer, Dr. Helen Thackray; Chief Medical Officer, Dr. Donald Fong; and our new Chief Financial Officer, Babar Ghias. Following our remarks, we will answer your questions.
Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
